Xu Jia, Yao Ye, Zhuang Qisheng, Li Zixuan, Zhang Min, Wang Shouan, Hu Hongxin, Ye Jianbin
School of Basic Medicine Science, Fujian Province, Putian University, Key Laboratory of Translational Tumor Medicine in , Putian City, 351100, Fujian Province, China.
The Affiliated Hospital of Putian University, Putian City, 351100, Fujian Province, China.
Parasit Vectors. 2025 Jan 13;18(1):6. doi: 10.1186/s13071-024-06656-0.
A fundamental tenet of the hygiene theory is the inverse association between helminth infections and the emergence of immune-mediated diseases. Research has been done to clarify the processes by which helminth-derived molecules can inhibit immunological disorders. This study aimed to evaluate the ability of Trichinella spiralis chitinase (Ts-chit) to ameliorate the symptoms of allergic airway inflammation.
Recombinant Trichinella spiralis chitinase (rTs-chit) was expressed in Escherichia coli BL21, and its structural homology to murine acidic mammalian chitinase (AMCase) was comprehensively analyzed. The expression of Ts-chit was examined across all T. spiralis life stages. To explore its immunomodulatory potential, a murine model of allergen-induced airway inflammation was established. The effects of rTs-chit were evaluated by assessing airway hyperresponsiveness and cytokine profiles in bronchoalveolar lavage fluid and performing detailed histopathological and immunohistochemical analyses.
Recombinant Ts-chit (rTs-chit) was successfully expressed in E. coli BL21, showing strong structural similarity to murine acidic mammalian chitinase (AMCase). Expression profiling revealed that Ts-chit is present throughout all stages of the T. spiralis life cycle. In an allergic airway inflammation model, rTs-chit reduced weight loss and lung inflammation, lowering inflammatory cell infiltration and Th2 cytokines (IL-4, IL-5, IL-13) while increasing the immunosuppressive cytokine IL-10. Additionally, rTs-chit treatment decreased the expression of GATA3, arginase-1, MCP-1, CCL-11, and AMCase, along with reducing OVA-specific IgE, IgG, and IgG1 levels, suggesting its potential as an immunomodulatory agent.
This study highlights rTs-chit's potential as a therapeutic agent for allergic airway diseases, leveraging its structural similarity to host chitinases to regulate Th2 responses and inflammatory pathways. The findings provide new insights into helminth-derived proteins as promising candidates for immune-based therapies.
卫生学理论的一个基本信条是蠕虫感染与免疫介导疾病的出现之间存在负相关。人们已经开展研究以阐明蠕虫衍生分子抑制免疫紊乱的过程。本研究旨在评估旋毛虫几丁质酶(Ts-chit)改善过敏性气道炎症症状的能力。
重组旋毛虫几丁质酶(rTs-chit)在大肠杆菌BL21中表达,并对其与小鼠酸性哺乳动物几丁质酶(AMCase)的结构同源性进行了全面分析。在旋毛虫的所有生命阶段检测Ts-chit的表达。为了探究其免疫调节潜力,建立了变应原诱导的气道炎症小鼠模型。通过评估气道高反应性、支气管肺泡灌洗液中的细胞因子谱以及进行详细的组织病理学和免疫组织化学分析来评估rTs-chit的作用。
重组Ts-chit(rTs-chit)在大肠杆菌BL21中成功表达,显示出与小鼠酸性哺乳动物几丁质酶(AMCase)有很强的结构相似性。表达谱分析表明,Ts-chit存在于旋毛虫生命周期的所有阶段。在过敏性气道炎症模型中,rTs-chit减轻了体重减轻和肺部炎症,减少了炎性细胞浸润和Th2细胞因子(IL-4、IL-5、IL-13),同时增加了免疫抑制细胞因子IL-10。此外,rTs-chit治疗降低了GATA3、精氨酸酶-1、MCP-1、CCL-11和AMCase的表达,同时降低了OVA特异性IgE、IgG和IgG1水平,表明其作为免疫调节剂的潜力。
本研究强调了rTs-chit作为过敏性气道疾病治疗剂的潜力,利用其与宿主几丁质酶的结构相似性来调节Th2反应和炎症途径。这些发现为蠕虫衍生蛋白作为基于免疫疗法的有前途候选物提供了新的见解。